Why Co-Diagnostics Stock Rose 15.8% on Monday

·3-min read
Why Co-Diagnostics Stock Rose 15.8% on Monday

The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting